Collin Blakely MD, PhD retweetledi
Collin Blakely MD, PhD
1.3K posts
Collin Blakely MD, PhD
@collin_blakely
Associate Professor of thoracic medical oncology and clinical scientist at UCSF. Opinions are my own. https://t.co/oIdKg9VmyW
San Francisco, CA Katılım Ocak 2016
111 Takip Edilen1.1K Takipçiler
Collin Blakely MD, PhD retweetledi
"It’s hard to recall a regulator who has done as much damage to medical innovation in as little time as Vinay Prasad."
What an opening sentence!
English
Collin Blakely MD, PhD retweetledi
Collin Blakely MD, PhD retweetledi
Collin Blakely MD, PhD retweetledi
THE SEATTLE SEAHAWKS ARE SUPER BOWL LX CHAMPIONS. 🏆
English
Collin Blakely MD, PhD retweetledi
If you ever wondered how all those people could remain close to Epstein even after his 2008 conviction, just look at the people who were happy to have dinner with MBS last night. It’s all one big club for the elite and wealthy, and having money outweighs any heinous crimes you may have committed.
Brian Schwartz@schwartzbWSJ
NEW: Dozens of executives RSVP’d for the White House dinner with Mohammed bin Salman per lists I obtained. Expected attendees: Blackstone CEO Stephen Schwarzman, Trump Org. exec and Trump’s son Donald Trump Jr., Apple CEO Tim Cook and Tesla CEO Elon Musk. Cristiano Ronaldo, Michael Dell and Bill Ackman also RSVP’d
English
Taking nothing away from the great Aaron Judge, I’d ask those who voted for him this: what more did Cal have to do to get your vote? 3 more home runs? Catch in 10 more games? Be better defensively? What more?
English
@NikoTamurian If Cal played for the Yankees he would have been the unanimous MVP.
English
The more the vote sets in...
The more ridiculous it is--
Judge had a great season, obviously.
Raleigh did things we had never seen from a catcher & switch-hitter.
Cal had more home runs &RBI while playing the most demanding position. Calling games, too.
Makes no sense.
English
Collin Blakely MD, PhD retweetledi
Collin Blakely MD, PhD retweetledi
Collin Blakely MD, PhD retweetledi
.@dr_demetre, the Dir. of the Nat’l Center for Immunization and Respiratory Diseases at the CDC, just posted this on instagram.
Yes it’s that bad.
We are in uncharted territory.
English
Collin Blakely MD, PhD retweetledi
FACT: Adolf Hitler and the Nazi regime frequently removed, silenced, or punished government officials, scientists, and bureaucrats who presented information or data that contradicted Nazi ideology or propaganda goals.
English
Collin Blakely MD, PhD retweetledi
How should clinicians approach resectable EGFR-mutant #NSCLC? On the latest #LungCancerConsidered episode, @StephenVLiu moderates a case discussion with @collin_blakely and @susu_mail0513, covering evolving strategies and clinical decision-making.
🎧 bit.ly/VTBregfrnsclc
English
Collin Blakely MD, PhD retweetledi
If they can handcuff a U.S. Senator for asking a question, imagine what they will do to you.
English
Collin Blakely MD, PhD retweetledi
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study ➡️ brnw.ch/21wLAW8 @collin_blakely #NSCLC #lcsm
English
@Timothee_MD @Alfdoc2 @dr_yakupergun @OncoAlert @VPrasadMDMPH I think when someone dismisses an entire trial in a one line tweet, the author of the trial should be able to ask for more details on what the appropriate alternative trial design would be.
English
@collin_blakely @Alfdoc2 @dr_yakupergun @OncoAlert Should only those running trials give opinions on them?
It's like saying only chefs can judge if the food is good. (quoting @VPrasadMDMPH)
I believe the opposite: unbiased assessments come from those not involved, to avoid personal or intellectual conflicts of interest.
English
Neoadjuvant Osimertinib for resectable (stage I-IIIA) EGFRm+ NSCLC
27 pts, (1 or 2 months neoadj Osi)
MPR➡️15%
The study did not meet its primary endpoint‼️
Is the duration of treatment enough?
📌Phase 3 NeoADAURA (Osi+ChT) is ongoing
@OncoAlert
ascopubs.org/doi/10.1200/JC…
English
@Alfdoc2 @dr_yakupergun @OncoAlert I agree that if I were to design a trial today, MPR would not be my preferred endpoint, but we had to start somewhere.
English
@Alfdoc2 @dr_yakupergun @OncoAlert This trial was designed in 2016 after numerous discussions with the FDA, Aztrazeneca, pathologists etc. This was when the only neoadjuvant or adjuvant data available for NSCLC were with chemo. Please share what a more appropriate endpoint would have been.
English
@oncomedicnat @StephenVLiu @JCO_ASCO While adding chemo may be the most obvious solution, we are using the samples from this trial to more precisely identify drivers of disease persistence. Targeted those mechanisms will be the key. More to come…
English
Phase II study of neoadjuvant osimertinib for resectable #EGFR NSCLC @JCO_ASCO from Dr. @collin_blakely et al. MPR rate only 14.8% with no pCR observed in 27 pts. Radiographic RR 52%. Osimertinib did not delay or negatively impact surgery.
ascopubs.org/doi/10.1200/JC…
English